David has made over 13 trades of the Menlo Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 3,355 units of MNLO stock worth 7,884$ on 1 July 2019.
The largest trade he's ever made was selling 8,238 units of Menlo Therapeutics stock on 8 August 2018 worth over 46,792$. On average, David trades about 1,223 units every 21 days since 2018. As of 1 July 2019 he still owns at least 211,240 units of Menlo Therapeutics stock.
You can see the complete history of Mr. Domzalski stock trades at the bottom of the page.
David Domzalski serves as Chief Executive Officer, Director of the Company. From July 2017 until the Closing Date, Mr. Domzalski served as the Chief Executive Officer of Foamix. He also served as a director of Foamix beginning in January 2018. Mr. Domzalski’s tenure with Foamix began in April 2014 and previously served as President of its U.S. subsidiary. Previously, Mr. Domzalski was the Vice President of Sales and Marketing at LEO Pharm Inc. from 2009 to 2013. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College, Allentown, Pennsylvania.
David Domzalski is 53, he's been the Chief Executive Officer、 Director of Menlo Therapeutics since 2020. There are 6 older and 3 younger executives at Menlo Therapeutics. The oldest executive at Menlo Therapeutics, Inc. is Rex Bright, 79, who is the Director.
David's mailing address filed with the SEC is Rehovot, Israel.
Over the last 7 years, insiders at Menlo Therapeutics have traded over 3,825,000$ worth of Menlo Therapeutics stock and bought 3,655,938 units worth 21,205,011$ . The most active insiders traders include Advisors Llcperceptive Life...、Llc Fmr、Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of 572,944$. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth 111,000$.
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.
Menlo Therapeutics executives and other stock owners filed with the SEC include: